Acino and Teva Reach an Agreement to Complete Acquisition of Mepha's Production and R&D Facilities and MENA/LATAM/Asian Businesses
Acino Pharma AG ("Acino"), a wholly owned subsidiary of Acino Holding AG (SIX: ACIN), has signed an agreement with Teva Pharmaceutical Industries Ltd. to purchase the Middle Eastern, African, Latin American and Asian businesses from Mepha LLC, a wholly owned subsidiary of Teva, and certain other subsidiaries of Teva. The combined asset and share transaction includes the acquisition of the Mepha site in Aesch, with its production and R&D facilities and has an aggregated value of EUR 94 million.
Bär & Karrer acts as Swiss legal advisor to Acino. The Bär & Karrer team includes Thomas Reutter, Christoph Neeracher, Markus Wang (IP), Mani Reinert (Merger Control), Raoul Stocker (tax), Daniel Raun, Daniel Heiniger, Luca Jagmetti and Valentin Baltzer.